Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astrazeneca Ord Shs AZNCF

Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (OTCPK:AZNCF)

Statement re Credit Ratings

UK Regulatory news services, from the LSE July 27, 2016

Net Asset Value(s)

UK Regulatory news services, from the BW July 27, 2016

FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis

Canada NewsWire July 19, 2016

QTERN (saxa/dapa) EU approved for type-2 diabetes

UK Regulatory news services, from the LSE July 19, 2016

TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL

UK Regulatory news services, from the LSE July 18, 2016

TAGRISSO® (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line Lung Cancer Trial

Business Wire July 18, 2016

Second Price Monitoring Extn

UK Regulatory news services, from the LSE July 14, 2016

Price Monitoring Extension

UK Regulatory news services, from the LSE July 14, 2016

Trading Statement

UK Regulatory news services, from the LSE July 13, 2016

AZ resolves Faslodex patent litigation in the US

UK Regulatory news services, from the LSE July 13, 2016

Slade Lane Planning Application

UK Regulatory news services, from the LSE July 13, 2016

Believe It: Brexit Isn't All Bad For U.K. ETFs

Benzinga.com  July 11, 2016

Here's Why Valeant Is Happy To Relinquish Its European Brodalumab Rights

Benzinga.com  July 7, 2016

AZ enters licensing agreements with LEO Pharma

UK Regulatory news services, from the LSE July 1, 2016

Total Voting Rights

UK Regulatory news services, from the BW July 1, 2016

Transaction in Own Shares

UK Regulatory news services, from the BW July 1, 2016

Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe

Canada NewsWire July 1, 2016

Zavicefta approved in EU

UK Regulatory news services, from the LSE June 28, 2016

Organisational changes

UK Regulatory news services, from the LSE June 28, 2016

Operations and Investment Update

UK Regulatory news services, from the LSE June 28, 2016